RARE insider transactions
Ultragenyx Pharmaceutical Inc. (RARE) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for RARE
- Chief Financial Officer Horn Howard sold $110,602 worth of shares (4,653 units at $23.77), decreasing direct ownership by 4% to 105,689 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Director Fust Matthew K was granted 7,751 shares, increasing direct ownership by 30% to 33,696 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Director Suliman Shehnaaz was granted 7,751 shares and sold $144,189 worth of shares (5,740 units at $25.12), increasing direct ownership by 8% to 27,951 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Director Ray Amrit was granted 7,751 shares, increasing direct ownership by 33% to 31,116 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Director Sanders Corazon (Corsee) D. was granted 7,751 shares, increasing direct ownership by 51% to 23,095 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Director Narachi Michael was granted 7,751 shares, increasing direct ownership by 24% to 40,441 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Director Welch Daniel G was granted 7,751 shares, increasing direct ownership by 24% to 40,441 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Director Dunsire Deborah was granted 7,751 shares, increasing direct ownership by 25% to 38,566 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- EVP and Chief Medical Officer Crombez Eric sold $8,586 worth of shares (344 units at $24.96), decreasing direct ownership by 0.31% to 111,189 units (SEC Form 4) to cover taxes4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Chief Financial Officer Horn Howard sold $116,607 worth of shares (4,683 units at $24.90), decreasing direct ownership by 4% to 110,342 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SVP, Chief Accounting Officer Huizenga Theodore Alan was granted 20,241 shares, increasing direct ownership by 42% to 68,911 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SEC Form 4 filed by Kakkis Emil D4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SEC Form 4 filed by Huang Dennis Karl4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SEC Form 4 filed by Pinion John Richard4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SEC Form 4 filed by Parschauer Karah Herdman4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SEC Form 4 filed by Harris Erik4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SEC Form 4 filed by Crombez Eric4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SEC Form 4 filed by Horn Howard4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SEC Form 4 filed by Horn Howard4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SEC Form 4 filed by Ultragenyx Pharmaceutical Inc.4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Officer Pinion John Richard was granted 11,137 shares and sold $228,661 worth of shares (10,029 units at $22.80), increasing direct ownership by 1% to 110,026 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- EVP & Chief Commercial Officer Harris Erik was granted 11,643 shares and sold $240,289 worth of shares (10,539 units at $22.80), increasing direct ownership by 2% to 89,515 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- President & CEO Kakkis Emil D was granted 71,177 shares and sold $1,240,411 worth of shares (54,404 units at $22.80), increasing direct ownership by 3% to 658,994 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- EVP and Chief Legal Officer Parschauer Karah Herdman was granted 11,137 shares and sold $185,478 worth of shares (8,135 units at $22.80), increasing direct ownership by 4% to 76,346 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SVP, Chief Accounting Officer Huizenga Theodore Alan covered exercise/tax liability with 148 shares and sold $37,210 worth of shares (1,632 units at $22.80), decreasing direct ownership by 4% to 48,670 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Chief Financial Officer Horn Howard was granted 6,143 shares and sold $227,538 worth of shares (10,044 units at $22.65), decreasing direct ownership by 4% to 85,034 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- EVP and Chief Medical Officer Crombez Eric was granted 11,643 shares and sold $160,261 worth of shares (7,029 units at $22.80), increasing direct ownership by 7% to 76,301 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Officer Huang Dennis Karl covered exercise/tax liability with 999 shares and was granted 11,137 shares, increasing direct ownership by 9% to 124,729 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Chief Financial Officer Horn Howard sold $72,117 worth of shares (3,061 units at $23.56), decreasing direct ownership by 3% to 88,935 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Chief Financial Officer Horn Howard sold $71,946 worth of shares (3,150 units at $22.84), decreasing direct ownership by 3% to 91,996 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SVP, Chief Accounting Officer Huizenga Theodore Alan sold $2,922 worth of shares (85 units at $34.38), decreasing direct ownership by 0.17% to 50,450 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Chief Financial Officer Horn Howard sold $112,087 worth of shares (3,081 units at $36.38), decreasing direct ownership by 3% to 95,146 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Chief Financial Officer Horn Howard sold $250,252 worth of shares (7,942 units at $31.51), decreasing direct ownership by 7% to 98,227 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SVP, Chief Accounting Officer Huizenga Theodore Alan sold $1,867 worth of shares (64 units at $29.17), decreasing direct ownership by 0.13% to 50,242 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- EVP and Chief Legal Officer Parschauer Karah Herdman sold $76,366 worth of shares (2,450 units at $31.17), decreasing direct ownership by 3% to 73,271 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SVP, Chief Accounting Officer Huizenga Theodore Alan sold $2,637 worth of shares (84 units at $31.39), decreasing direct ownership by 0.17% to 50,306 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Director Sanders Corazon (Corsee) D. sold $89,923 worth of shares (2,405 units at $37.39), decreasing direct ownership by 14% to 15,344 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Director Suliman Shehnaaz was granted 5,740 shares, increasing direct ownership by 28% to 25,940 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Director Welch Daniel G was granted 5,740 shares, increasing direct ownership by 21% to 32,690 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Director Sanders Corazon (Corsee) D. was granted 5,740 shares, increasing direct ownership by 48% to 17,749 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Director Narachi Michael was granted 5,740 shares, increasing direct ownership by 21% to 32,690 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Director Fust Matthew K was granted 5,740 shares, increasing direct ownership by 28% to 25,945 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Director Dunsire Deborah was granted 5,740 shares, increasing direct ownership by 23% to 30,815 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Director Ray Amrit was granted 5,740 shares, increasing direct ownership by 33% to 23,365 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- EVP and Chief Medical Officer Crombez Eric sold $28,901 worth of shares (762 units at $37.93), decreasing direct ownership by 0.55% to 71,530 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Chief Financial Officer Horn Howard sold $72,114 worth of shares (1,785 units at $40.40), decreasing direct ownership by 2% to 106,169 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- CBO & EVP Kassberg Thomas Richard was granted 18,443 shares, sold $253,779 worth of shares (6,028 units at $42.10) and covered exercise/tax liability with 508 shares, increasing direct ownership by 5% to 264,730 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- EVP and Chief Legal Officer Parschauer Karah Herdman was granted 18,443 shares and sold $540,817 worth of shares (12,846 units at $42.10), increasing direct ownership by 8% to 75,287 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- EVP and Chief Medical Officer Crombez Eric was granted 31,784 shares and sold $376,584 worth of shares (8,945 units at $42.10), increasing direct ownership by 49% to 71,922 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Officer Pinion John Richard was granted 32,937 shares, sold $607,882 worth of shares (14,439 units at $42.10) and covered exercise/tax liability with 31 shares, increasing direct ownership by 21% to 108,428 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- President & CEO Kakkis Emil D was granted 150,560 shares and sold $4,153,571 worth of shares (98,434 units at $42.20), increasing direct ownership by 14% to 641,731 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- EVP & Chief Commercial Officer Harris Erik was granted 35,256 shares and sold $635,836 worth of shares (15,103 units at $42.10), increasing direct ownership by 31% to 87,855 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Officer Huang Dennis Karl was granted 32,937 shares and covered exercise/tax liability with 1,348 shares, increasing direct ownership by 38% to 114,591 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SVP, Chief Accounting Officer Huizenga Theodore Alan was granted 9,392 shares, sold $40,711 worth of shares (967 units at $42.10) and covered exercise/tax liability with 141 shares, increasing direct ownership by 20% to 50,124 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Chief Financial Officer Horn Howard was granted 15,653 shares, increasing direct ownership by 17% to 107,954 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- EVP and Chief Legal Officer Parschauer Karah Herdman sold $128,224 worth of shares (2,990 units at $42.88) and was granted 14,494 shares, increasing direct ownership by 20% to 69,690 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- President & CEO Kakkis Emil D sold $495,231 worth of shares (11,727 units at $42.23) (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SVP, Chief Accounting Officer Huizenga Theodore Alan gifted 648 shares, decreasing direct ownership by 2% to 41,840 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- President & CEO Kakkis Emil D gifted 20,000 shares and sold $413,650 worth of shares (8,273 units at $50.00) (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- Chief Financial Officer Horn Howard sold $393,853 worth of shares (7,465 units at $52.76), decreasing direct ownership by 7% to 92,301 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)